Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension

Trial Profile

Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2015

At a glance

  • Drugs Beloranib (Primary)
  • Indications Hypothalamic disorders; Obesity
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Zafgen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Mar 2015 Results presented at The 97th Annual Meeting of the Endocrine Society.
    • 07 Mar 2015 According to a Zafgen media release, results were presented at the Endocrine Society Annual Meeting (ENDO) 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top